Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Consolidated Net Income: 2018-2024

Historic Consolidated Net Income for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$45.3 million.

  • Silence Therapeutics' Consolidated Net Income rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 15.29%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Silence Therapeutics' Consolidated Net Income amounted to -$45.3 million in FY2024, which was up 16.45% from -$54.2 million recorded in FY2023.
  • Silence Therapeutics' Consolidated Net Income's 5-year high stood at -$41.8 million during FY2020, with a 5-year trough of -$59.3 million in FY2022.
  • In the last 3 years, Silence Therapeutics' Consolidated Net Income had a median value of -$54.2 million in 2023 and averaged -$52.9 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 67.16% in 2020, then increased by 16.45% in 2024.
  • Over the past 5 years, Silence Therapeutics' Consolidated Net Income (Yearly) stood at -$41.8 million in 2020, then fell by 29.74% to -$54.2 million in 2021, then declined by 9.38% to -$59.3 million in 2022, then grew by 8.57% to -$54.2 million in 2023, then grew by 16.45% to -$45.3 million in 2024.